Business
Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On Track
Continues to manufacture and deliver therapies and advance R&D efforts during COVID-19 pandemic Expects to submit AQST-108 (epinephrine) IND by June 2020 and
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"Continues to manufacture and deliver therapies and advance R&D efforts during COVID-19 pandemic Expects to submit AQST-108 (epinephrine) IND by June 2020 and to commence PK trials by end of 2020Continues to advance Libervant (diazepam) through FDA review process as expectedReaffirms full year 2020 guidance including revenue, adjusted EBITDA and cash burn Hosts investment community conference call at 8:00 am ET on May 6, 2020 WARREN, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent developments in its business. \n Keith J. Kendall, President and Chief Executive Officer of Aquestive, stated, “While fulfilling our responsibility to keep our colleagues, neighbors and society as a whole safe during this unprecedented crisis caused by the novel coronavirus pandemic, we are continuing to advance the important work of the Company, ensuring the medications our patients depend on each day remain available to them without interruption. At this time, Aquestive continues to produce therapies as expected and our R&D labs continue to advance key pipeline therapies including Libervant™ (diazepam) Buccal Film for the management of seizure clusters, and AQST-108 sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis. We are continuing to interact with the FDA and responding, as expected, to information requests by the FDA related to our NDA filing for Libervant.” “We are continuing to prudently manage our cash flow and have begun the process to seek to monetize the anticipated royalties associated with Sunovion’s apomorphine therapy, if approved by the FDA, with an expected PDUFA goal date of May 21, 2020. We have begun to communicate with potential investors and will consider market conditions, COVID related or otherwise, structure and timing of any monetization to enable us to provide appropriate additional capital for the Company. Based on our planning and expectations, we believe that we are positioned with current cash resources and a potential non-dilutive apomorphine monetization to e...